LATEST
BLK Global PLC: Preliminary Results for the Year Ended 30 June 2026Scientists Launch Legal Challenge to DEA's Proposed Psychedelic Scheduling, Which Would Criminalize Research Compounds and Jeopardize FDA Breakthrough Therapy for Postpartum DepressionTrauma Nurse Builds Clinical Apps Between ShiftsObama Criticises Israel as His Own Record Comes Under ScrutinyVIORA and BioTeke Strengthen Strategic Partnership to Advance Saliva Pregnancy Testing Across EuropeAI Startup AvalonX Emerges From Stealth With $10 Million in Funding From Ridown CapitalGaza, the October 7 Warnings and the Human Cost of Israel’s Security StrategyWhy Good Strategies Lose Momentum Before the Numbers Show ItTransatlantic Coalition: European and Canadian News and Magazine Publishers Unite to Defend Free and Pluralistic MediaDan Rather, Wavelength, Original Productions and Anchor Entertainment Partner to Make RATHER Documentary Free to Stream on YouTube Beginning Monday, October 26, in Support of Independent Journalism and Free SpeechBLK Global PLC: Preliminary Results for the Year Ended 30 June 2026Scientists Launch Legal Challenge to DEA's Proposed Psychedelic Scheduling, Which Would Criminalize Research Compounds and Jeopardize FDA Breakthrough Therapy for Postpartum DepressionTrauma Nurse Builds Clinical Apps Between ShiftsObama Criticises Israel as His Own Record Comes Under ScrutinyVIORA and BioTeke Strengthen Strategic Partnership to Advance Saliva Pregnancy Testing Across EuropeAI Startup AvalonX Emerges From Stealth With $10 Million in Funding From Ridown CapitalGaza, the October 7 Warnings and the Human Cost of Israel’s Security StrategyWhy Good Strategies Lose Momentum Before the Numbers Show ItTransatlantic Coalition: European and Canadian News and Magazine Publishers Unite to Defend Free and Pluralistic MediaDan Rather, Wavelength, Original Productions and Anchor Entertainment Partner to Make RATHER Documentary Free to Stream on YouTube Beginning Monday, October 26, in Support of Independent Journalism and Free Speech
Americas

Nexus Pharmaceuticals Receives Fda Approval for Tranexamic Acid in 0.7% Sodium Chloride Injection

“We are thrilled to be expanding our product line of ready-to-use critical-need products,” says Omair Ahmed, Chief Operating Officer. “This approval demonstrates Nexus’ dedication to providing safe and convenient medication options to clinicians and patients.” Features and benefits of Tranexamic Acid in 0.7% Sodium Chloride include:

• Accelerates healing time and reduces need for blood transfusions • Can provide pain control when used post-operative or in relation to injury • Minimizes damage to wound tissue and promotes new, healthy tissue growth

Tranexamic Acid in 0.7% Sodium Chloride will be available in packs of ten 1,000 mg/100 mL IV bags. Order directly through your Wholesaler or from Customer Service at 888-806-4606.

Nexus Pharmaceuticals LLC, a US-based healthcare company, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor intensive, and more streamlined in practice. Nexus ensures that its high-quality drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most.

www.nexuspharma.net

Related articles

Top